WallStreetZenWallStreetZen

NASDAQ: MLTX
Moonlake Immunotherapeutics Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for MLTX

Based on 5 analysts offering 12 month price targets for Moonlake Immunotherapeutics

Min Forecast
$61.00+37.98%
Avg Forecast
$73.40+66.03%
Max Forecast
$100.00+126.19%

Should I buy or sell MLTX stock?

Based on 5 analysts offering ratings for Moonlake Immunotherapeutics.

Buy
Strong Buy
1 analysts 20%
Buy
4 analysts 80%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although MLTX's forecast from analysts indicates a "Buy", our proven Zen Rating quant model rates MLTX as a "Sell". Stocks with a Zen Rating of Sell have had an average return of -4.50% per year. Learn More

Be the first to know when Wall Street analysts revise their MLTX stock forecasts and price targets.

MLTX stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-06-03
lockedlocked$00.00+00.00%2025-05-19
lockedlocked$00.00+00.00%2025-05-13
lockedlocked$00.00+00.00%2025-02-27
lockedlocked$00.00+00.00%2025-02-27

1 of 1

Forecast return on equity

Is MLTX forecast to generate an efficient return?

Company
17.49%
Industry
140.91%
Market
90.47%
MLTX's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is MLTX forecast to generate an efficient return on assets?

Company
13.94%
Industry
32.45%
MLTX is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

MLTX earnings per share forecast

What is MLTX's earnings per share in the next 3 years based on estimates from 8 analysts?

Avg 1 year Forecast
-$2.87
Avg 2 year Forecast
-$3.71
Avg 3 year Forecast
-$3.41

MLTX revenue forecast

What is MLTX's revenue in the next 3 years based on estimates from 4 analysts?

Avg 1 year Forecast
$125.3M
Avg 2 year Forecast
$578.9M
Avg 3 year Forecast
$1.4B

MLTX vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
MLTX$44.21$73.40+66.03%Buy
CPRX$23.53$32.50+38.12%Strong Buy
VKTX$26.08$79.00+202.91%Strong Buy
AAPG$31.51N/AN/A
IBRX$3.07$11.40+271.34%Strong Buy
View Top Biotech Stocks

Moonlake Immunotherapeutics Stock Forecast FAQ

Is Moonlake Immunotherapeutics Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 5 Wall Street analysts covering (NASDAQ: MLTX) stock is to Buy MLTX stock.

Out of 5 analysts, 1 (20%) are recommending MLTX as a Strong Buy, 4 (80%) are recommending MLTX as a Buy, 0 (0%) are recommending MLTX as a Hold, 0 (0%) are recommending MLTX as a Sell, and 0 (0%) are recommending MLTX as a Strong Sell.

If you're new to stock investing, here's how to buy Moonlake Immunotherapeutics stock.

What is MLTX's earnings growth forecast for 2025-2027?

(NASDAQ: MLTX) Moonlake Immunotherapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 10.6%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.33%.

Moonlake Immunotherapeutics's earnings in 2025 is -$147,827,879.On average, 8 Wall Street analysts forecast MLTX's earnings for 2025 to be -$184,026,701, with the lowest MLTX earnings forecast at -$202,241,255, and the highest MLTX earnings forecast at -$139,963,789. On average, 8 Wall Street analysts forecast MLTX's earnings for 2026 to be -$238,278,720, with the lowest MLTX earnings forecast at -$322,943,972, and the highest MLTX earnings forecast at -$147,668,218.

In 2027, MLTX is forecast to generate -$219,094,693 in earnings, with the lowest earnings forecast at -$318,449,722 and the highest earnings forecast at -$159,866,897.

What is MLTX's revenue growth forecast for 2027-2029?

(NASDAQ: MLTX) Moonlake Immunotherapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.38%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.68%.

Moonlake Immunotherapeutics's revenue in 2025 is $0.On average, 4 Wall Street analysts forecast MLTX's revenue for 2027 to be $8,043,873,050, with the lowest MLTX revenue forecast at $3,938,889,204, and the highest MLTX revenue forecast at $11,742,833,502. On average, 4 Wall Street analysts forecast MLTX's revenue for 2028 to be $37,165,522,303, with the lowest MLTX revenue forecast at $17,752,287,935, and the highest MLTX revenue forecast at $56,314,879,985.

In 2029, MLTX is forecast to generate $87,791,323,684 in revenue, with the lowest revenue forecast at $37,873,687,713 and the highest revenue forecast at $168,603,076,948.

What is MLTX's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: MLTX) forecast ROA is 13.94%, which is lower than the forecast US Biotechnology industry average of 32.45%.

What is MLTX's Price Target?

According to 5 Wall Street analysts that have issued a 1 year MLTX price target, the average MLTX price target is $73.40, with the highest MLTX stock price forecast at $100.00 and the lowest MLTX stock price forecast at $61.00.

On average, Wall Street analysts predict that Moonlake Immunotherapeutics's share price could reach $73.40 by Jun 3, 2026. The average Moonlake Immunotherapeutics stock price prediction forecasts a potential upside of 66.03% from the current MLTX share price of $44.21.

What is MLTX's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: MLTX) Moonlake Immunotherapeutics's current Earnings Per Share (EPS) is -$2.30. On average, analysts forecast that MLTX's EPS will be -$2.87 for 2025, with the lowest EPS forecast at -$3.15, and the highest EPS forecast at -$2.18. On average, analysts forecast that MLTX's EPS will be -$3.71 for 2026, with the lowest EPS forecast at -$5.03, and the highest EPS forecast at -$2.30. In 2027, MLTX's EPS is forecast to hit -$3.41 (min: -$4.96, max: -$2.49).

What is MLTX's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: MLTX) forecast ROE is 17.49%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.